MOPEAD newsletter 01

Interview with Mercè Boada, MOPEAD project leader, Founder and Medical Director of Fundació ACE, Institut Català de Neurociències Aplicades. The difficulty of diagnosing Alzheimer’s disease (AD) in the very early stages lies in the belief of the general p...

Interview with Laura Campo, MOPEAD project leader, International Corporate Affairs, Alzheimer’s disease at Eli Lilly and Company. The current academic understanding of Alzheimer’s disease (AD) pathogenesis and management emphasizes the need for an early d...

Interview with Bengt Winblad, Professor of Geriatric Medicine at the Karolinska Institutet, Head of Division of Neurogeriatrics and Director of the Swedish Brain Power research network. The ageing of the population in Europe is leading to an increase in t...

Interview with Annette Dumas, ASDM Consulting, EU Affairs Director Dementia, a condition that mainly affects elderly people, has been recognised as a public health priority worldwide. We now have evidence that early diagnosis leads to significant socio-ec...

The concept of Citizen Science can be described as public participation in scientific research using the web. The development of new technologies is leading to an exponential growth of projects and initiatives based on Citizen Science. This approach will b...

Since 2008, Open House days have been a key Fundació ACE activity, regularly offering free memory check-ups. This initiative has been launched under the slogan “If you check your cholesterol and sugar… why not check your memory too?”. The main objective is...

The vast majority of elderly subjects in many countries frequently visit the primary care physicians. However, there is evidence that in the majority of health systems dementia is frequently underdiagnosed in primary care settings. MOPEAD primary care base...

Diabetic patients have an almost two-fold higher risk of developing Alzheimer’s disease (AD) compared to age-matched non-diabetic subjects. There is evidence that type 2 diabetes (T2D) accelerates the progression of mild cognitive impairment to AD. MOPEAD...

Alzheimer Europe organized a Symposium supported by Eli Lilly on 4 October 2017 at its annual conference in Berlin. The symposium titled explored how these three public-private consortia sponsored by Horizon 2020 under the auspices of IMI and EFPIA, are ta...

Please reload

Please reload

©2018 MOPEAD

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No 115985. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations